Anales de la RANM

290 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 PREVENCIÓN INTEGRAL DEL CÁNCER DE CUELLO UTERINO José Antonio Vidart Aragón An RANM · Año 2019 · número 136 (03) · páginas 287 a 291 Si las generaciones siguientes de mujeres españolas siguen sufriendo la amenaza del CC será por en nues- tro país no hemos hecho lo que es debido. Aplicarnos a proteger adecuadamente del CC a las mujeres espa- ñolas es necesario y factible. 1. Zur Hausen H, Meinhof W , Scheiber W , Bor- nkamm GW .: Attempts to detect virus-specific DNA in human tumors. I. Nucleic acid hybridi- zations with complementary RNA of human wart virus. Int J Cancer. 1974; 13: 650-656. 2. Zur Hausen H.:Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 1991; 184(1): 9-13 3. Walboomers JM, Jacobs MV, Manos MM et al.: Human papillomavirus is a necessary cause of in- vasive cervical cancer worldwide. J Pathol. 1999; 189: 12-19. 4. Ghebreyesus TA.: WHO Meeting. Genève. 19 de Mayo 2018. 5. Peng S, Frazer IH, Fernando GJ, Zhou J.: Papi- llomavirus virus-like particles can deliver CTL epitopes to the MHC class I pathway. Virology. 1989; 240: 147-157. 6. Vacunas Profilácticas frente al Virus del Papi- loma Humano: Documento de Consenso de las Sociedades Científicas Españolas. 31 de Enero de 2007. J. Cortés Coordinador. SP.MSD Ediciones. 7. https://www.mscbs.gob.es/profesionales/salud- Publica/prevPromocion/vacunaciones/docs/Co- berturasVacunacion/Tabla11.pdf Acceso 29 de Abril de 2019. 8. Departamentos Médicos de Merck y GlaxoS- mithKline. Comunicación Personal. 9. Cortés J.: ¿Por qué no prescribes la vacuna VPH? En preparación. 10. http://www.ema.europa.eu/docs/en_GB/docu- ment_library/EPAR_-_Summary_for_the_pu- blic/human/000721/WC500024634.pdf. Acceso 2 de Mayo 2019. 11. http://www.ema.europa.eu/docs/en_GB/docu- ment_library/EPAR_-_Summary_for_the_pu- blic/human/003852/WC500189114.pdf. Acceso 3 de Mayo 2019. 12. Pollock KG.: Sustained cross-protection of the bivalent HPV vaccine.J Infect Dis. 2018; 10: 1515-1516. 13. World Health Organization: Weekly Epidemio- logical Report. Human Papillomavirus vaccine: WHO Position Paper May 2017.; 82: 241-268. 14. Palmer T.: Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vacci- ne at age 12-13 in Scotland: retrospective popu- lation study. Br Med J 2019; 365 doi: https://doi. org/10.1136/bmj.l1161 15. Sakamoto M, Miyagi E, Sumi Y et al.: Effective- ness on high-grade cervical abnormalities and long-term safety of the quadrivalent human pa- pillomavirus vaccine in Japanese women. J Infect Chemother. 2019 : S1341-321X(18)30302-7. doi: 10.1016/j.jiac.2019.02.012. 16. Herweijer E, Sundström K, Ploner A, Uhnoo I, Sparén P, Arnheim-Dahlström L. : Quadri- valent HPV vaccine effectiveness against high- grade cervical lesions by age at vaccination: A population-based study. Int J Cancer. 2016; 138: 2867-2874. 17. Cortés J.: Vacunatión and fake-news. Salut i For- ça. 2019; 391: 3. 18. Cortés J.: Estrategias de cribado del cáncer de cuello uterino. Prog Obstet Ginecol 2005; 48 Supl 1: 228 – 230. 19. Georgalis L, de Sanjosé S, Esnaola M, Bosch FX, M Diaz M.: Present and future of cervical cancer prevention in Spain: a cost-effectiveness analy- sis. Eur J Cancer Prev. 2016; 25: 430-439. 20. Cortés J, Bosch FX, Concha A, et al.: Spanish Cancer Association: Cervical Cancer Prevention Position Statement. Prog Obstet Ginecol.2019; 61: 510 – 544. 21. Papanicolaou GN, Traut HF.: The diagnostic value of vaginal smears in carcinoma of the uterus. 1941. Arch Pathol Lab Med. 1997; 121: 211-214 22. Papanicolaou GN.: New Cancer Diagnosis. Third Race Betterment Conference. Battje Creek, Mi- chigan, USA. 1928. 23. Christopherson WM, Parker JE, Drye JC.: Con- trol of cervical cancer. Preliminary report on community program. JAMA. 1962; 182: 179-182. 24. Walton RJ. : Editorial: The task force on cervi- cal cancer screening programs. Can Med Assoc J. 1976; 114(11): 981. 25. Cuzick J, Clavel C, Petry KU et al.: Overview of the European and North American studies on HPV testing in primary cervical cancer scree- ning. Int J Cancer. 2006; 119: 1095-1101. 26. Mayrand MH, Duarte-Franco E, Rodrigues I et al.: Human papillomavirus DNA versus Papani- colaou screening tests for cervical cancer. N Engl J Med. 2007; 357: 1579-1588. 27. van der Horst J, Siebers AG, Bulten J, Massu- ger LF , de Kok IM. : Increasing incidence of invasive and in situ cervical adenocarcinoma in the Netherlands during 2004-2013. Cancer Med. 2017; 6: 416-423. 28. Ronco G, Dillner J, Elfström KM et al for the International HPV screening working group: Ef- ficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four Euro- pean randomised controlled trials. Lancet. 2014; 383: 524-532. 29. Koliopoulos G, Nyaga VN, Santesso N et al.: Cy- tology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev. 2017; Aug 10;8: CD008587. 30. Quinn M, Babb P, Jones J, Allen E. : Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. Br Med J. 1999; 318: 904-908. 31. Torné A, del Pino M, Cusidó M et al.: Guía de cribado del cáncer de cuello de útero en España. Prog Obstet Ginecol. 2014; 57 (Supl.1): 1-53. 32. Ibáñez R, Alejo M, Combalia N et al.: Under- screened Women Remain Overrepresented in the Pool of Cervical Cancer Cases in Spain: A Need to Rethink the Screening Interventions. Biomed Res Int. 2015; vol.2015: Article ID 605375. 9 pages. BIBLIOGRAFÍA